`
`Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations
`
`Orange Book: Approved Drug Products with
`Therapeutic Equivalence Evaluations
`
`Mkt.Status
`
`Active Ingredient
`
`Proprietary
`Name
`
`Appl
`No
`
`Dosage
`Form
`
`Route
`
`Strength
`
`TE
`Code
`
`RLD
`
`RS
`
`RX
`
`RX
`
`OTC
`
`OTC
`
`LEVOCETIRIZINE
`DIHYDROCHLORIDE XYZAL
`
`LEVOCETIRIZINE
`DIHYDROCHLORIDE XYZAL
`
`LEVOCETIRIZINE
`DIHYDROCHLORIDE
`
`LEVOCETIRIZINE
`DIHYDROCHLORIDE
`
`XYZAL
`ALLERGY
`24HR
`XYZAL
`ALLERGY
`24HR
`
`N022157 SOLUTION ORAL
`
`2.5MG/5ML AA
`
`RLD
`
`N022064 TABLET
`
`ORAL
`
`5MG
`
`AB
`
`RLD
`
`RS
`
`N209090 SOLUTION ORAL
`
`2.5MG/5ML
`
`RLD
`
`RS
`
`N209089 TABLET
`
`ORAL
`
`5MG
`
`RLD
`
`RS
`
`Applicant
`Holder
`SANOFI
`AVENTIS
`US LLC
`SANOFI
`AVENTIS
`US LLC
`SANOFI
`AVENTIS
`US LLC
`SANOFI
`AVENTIS
`US LLC
`
`1/2
`
`
`
`6/6/2019
`
`Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations
`
`2/2
`
`